IMMUCELL CORP /DE/

Develops biotech health products for disease prevention in dairy and beef cattle.

ICCC | NDAQ

Overview

Corporate Details

ISIN(s):: US4525253062
LEI:
Country:: United States of America
Address:: 56 EVERGREEN DR, 4103 PORTLAND
Website:: https://immucell.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ImmuCell Corporation is an animal health biotechnology company that develops, manufactures, and markets scientifically-proven products to improve the health and productivity of dairy and beef cattle. The company's flagship product line, First Defense®, delivers 'Immediate Immunity™' to newborn calves, utilizing colostrum-derived antibodies to prevent scours caused by E. coli, coronavirus, and rotavirus. A key differentiator is ImmuCell's unique capability to concentrate, purify, and quantify these specific antibodies on a commercial scale. The company is also developing Re-Tain®, a nisin-based intramammary treatment for subclinical mastitis, as an alternative to traditional antibiotics. ImmuCell focuses on providing practical, cost-effective solutions for disease prevention, aiming to maximize genetic potential and reduce antibiotic reliance in the food chain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all IMMUCELL CORP /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMMUCELL CORP /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for IMMUCELL CORP /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ANTEROGEN CO., LTD. Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.	South Korea	065660
Antibiotice S.A. Develops and manufactures generic medicines and APIs, specializing in anti-infectives.	Romania	ATB
Apellis Pharmaceuticals, Inc. Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.	United States of America	APLS
Apimeds Pharmaceuticals US, Inc. Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.	United States of America	APUS
Apogee Therapeutics, Inc. Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.	United States of America	APGE
Apollomics Inc. A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.	United States of America	APLM
Apontis Pharma AG German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.	Germany	APPH
APPLIED DNA SCIENCES INC Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.	United States of America	APDN
Applied Therapeutics, Inc. Develops treatments for rare metabolic and central nervous system (CNS) disorders.	United States of America	APLT
Aprea Therapeutics, Inc. Developing precision cancer therapies targeting DNA Damage Response for solid tumors.	United States of America	APRE